Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis.

Literature DB >> 19144791

Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis.

Stephen P Saville¹, Anna L Lazzell, Ashok K Chaturvedi, Carlos Monteagudo, Jose L Lopez-Ribot.

Abstract

We report on the efficacy of the genetically engineered Candida albicans tet-NRG1 strain as an experimental live, attenuated vaccine against disseminated candidiasis in both immunocompetent and immunodeficient mice mostly dependent on T-cell immunity. This experimental vaccination model may represent an important tool to unravel the mechanisms of protective immunity during candidiasis.

Entities: Disease Species

Mesh：

Substances：

Year: 2009 PMID： 19144791 PMCID： PMC2650868 DOI： 10.1128/CVI.00480-08

Source DB: PubMed Journal: Clin Vaccine Immunol ISSN： 1556-679X

22 in total

Review 1. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences.

Authors: Dominique Sanglard; Frank C Odds
Journal: Lancet Infect Dis Date: 2002-02 Impact factor: 25.071

2. Role of complement C5 and T lymphocytes in pathogenesis of disseminated and mucosal candidiasis in susceptible DBA/2 mice.

Authors: Robert B Ashman; John M Papadimitriou; Alma Fulurija; Karen E Drysdale; Camile S Farah; Owen Naidoo; Theo Gotjamanos
Journal: Microb Pathog Date: 2003-02 Impact factor: 3.738

3. Hospital-acquired candidemia. The attributable mortality and excess length of stay.

Authors: S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal: Arch Intern Med Date: 1988-12

4. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors: C Beck-Sagué; W R Jarvis
Journal: J Infect Dis Date: 1993-05 Impact factor: 5.226

5. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection.

Authors: Stephen P Saville; Anna L Lazzell; Carlos Monteagudo; Jose L Lopez-Ribot
Journal: Eukaryot Cell Date: 2003-10

6. Attributable mortality of nosocomial candidemia, revisited.

Authors: Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen Herwaldt; Michael Pfaller; Daniel Diekema
Journal: Clin Infect Dis Date: 2003-10-08 Impact factor: 9.079

7. Course of primary candidiasis in T cell-depleted mice infected with attenuated variant cells.

Authors: L Romani; A Mencacci; E Cenci; P Mosci; G Vitellozzi; U Grohmann; P Puccetti; F Bistoni
Journal: J Infect Dis Date: 1992-12 Impact factor: 5.226

8. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.

Authors: S N Banerjee; T G Emori; D H Culver; R P Gaynes; W R Jarvis; T Horan; J R Edwards; J Tolson; T Henderson; W J Martone
Journal: Am J Med Date: 1991-09-16 Impact factor: 4.965

9. CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance.

Authors: L Romani; A Mencacci; E Cenci; R Spaccapelo; P Mosci; P Puccetti; F Bistoni
Journal: J Immunol Date: 1993-02-01 Impact factor: 5.422

10. Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice.

Authors: Stephen P Saville; Anna L Lazzell; Ashok K Chaturvedi; Carlos Monteagudo; Jose L Lopez-Ribot
Journal: Infect Immun Date: 2007-10-29 Impact factor: 3.441

17 in total

1. Protective effect of fungal extracellular vesicles against murine candidiasis.

Authors: Gabriele Vargas; Leandro Honorato; Allan Jefferson Guimarães; Marcio L Rodrigues; Flavia C G Reis; André M Vale; Anjana Ray; Joshua Daniel Nosanchuk; Leonardo Nimrichter
Journal: Cell Microbiol Date: 2020-07-22 Impact factor: 3.715

Review 2. Primary Cutaneous Coccidioidomycosis: An Update.

Authors: Irving Llibran Reyna-Rodríguez; Jorge Ocampo-Candiani; Sonia Chavez-Alvarez
Journal: Am J Clin Dermatol Date: 2020-10 Impact factor: 7.403

3. Examination of the pathogenic potential of Candida albicans filamentous cells in an animal model of haematogenously disseminated candidiasis.

Authors: Ian A Cleary; Sara M Reinhard; Anna L Lazzell; Carlos Monteagudo; Derek P Thomas; Jose L Lopez-Ribot; Stephen P Saville
Journal: FEMS Yeast Res Date: 2016-02-05 Impact factor: 2.796

4. The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion.

Authors: Priya Uppuluri; Christopher G Pierce; Derek P Thomas; Sarah S Bubeck; Stephen P Saville; Jose L Lopez-Ribot
Journal: Eukaryot Cell Date: 2010-08-13

Review 5. Vaccine immunity against fungal infections.

Authors: Som G Nanjappa; Bruce S Klein
Journal: Curr Opin Immunol Date: 2014-03-03 Impact factor: 7.486

Review 6. Development of vaccines for Candida albicans: fighting a skilled transformer.

Authors: Antonio Cassone
Journal: Nat Rev Microbiol Date: 2013-12 Impact factor: 60.633

7. A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis.

Authors: Jianmin Xue; Xia Chen; Dale Selby; Chiung-Yu Hung; Jieh-Juen Yu; Garry T Cole
Journal: Infect Immun Date: 2009-06-01 Impact factor: 3.441